George M. Milne Jr - Jan 6, 2022 Form 3 Insider Report for Amylyx Pharmaceuticals, Inc. (AMLX)

Role: Director
Signature: /s/ Joshua B. Cohen, as Attorney-in-Fact for George Mclean Milne
Stock symbol: AMLX
Transactions as of: Jan 6, 2022
Transactions value $: $0
Form type: 3
Date filed: 1/6/2022, 04:03 PM
Previous filing: Jun 16, 2021
Next filing: Mar 8, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	AMLX	Common Stock						195K	Jan 6, 2022	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	AMLX	Stock Option (Right to Buy)	Jan 6, 2022	Common Stock	2K	$6.88	Direct	F1
holding	AMLX	Series A Preferred Stock	Jan 6, 2022	Common Stock	262K		Direct	F2
holding	AMLX	Series B Preferred Stock	Jan 6, 2022	Common Stock	384K		Direct	F2
holding	AMLX	Series C-1 Preferred Stock	Jan 6, 2022	Common Stock	19.5K		Direct	F2
holding	AMLX	Series C-2 Preferred Stock	Jan 6, 2022	Common Stock	23.2K		Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	As of the date of this filing, 2,000 shares subject to such option vest and become exercisable in substantially equal monthly installments until February 19, 2022.
F2	Each share of Series A, Series B, Series C-1 and Series C-2 preferred stock (collectively the "Preferred Stock") is convertible on a one-for-one basis into Common Stock at any time at the election of the Reporting Person and will automatically convert upon the closing of the Issuer's initial public offering into the number of shares of the Issuer's Common Stock shown in column 3 without payment or further consideration. The Preferred Stock has no expiration date.

Content

As of the date of this filing, 2,000 shares subject to such option vest and become exercisable in substantially equal monthly installments until February 19, 2022.

Each share of Series A, Series B, Series C-1 and Series C-2 preferred stock (collectively the "Preferred Stock") is convertible on a one-for-one basis into Common Stock at any time at the election of the Reporting Person and will automatically convert upon the closing of the Issuer's initial public offering into the number of shares of the Issuer's Common Stock shown in column 3 without payment or further consideration. The Preferred Stock has no expiration date.